A Digital App to Help Patients with Acute Myeloid Leukemia
Official title: Multi-Site Randomized Controlled Trial of a Novel Digital Application (DREAMLAND) to Improve Outcomes for Patients with Acute Myeloid Leukemia
Funded at Massachusetts General Hospital · NIH-11141650 · Data updated 2026-11-12
This project explores if a new digital app can help patients with acute myeloid leukemia feel better and improve their well-being.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 19, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $565,763 |
| NIH project number | 5R01CA288550-02 |
| Project ID | NIH-11141650 on NIH RePORTER |
Who could benefit from this research
✓Could help
This opportunity is for patients newly diagnosed with acute myeloid leukemia who are about to start intensive chemotherapy and are hospitalized for treatment.
✕Less likely to help
Patients who are not newly diagnosed with acute myeloid leukemia or are not undergoing intensive chemotherapy may not find this app relevant to their current situation.
What this research studies
When you're diagnosed with acute myeloid leukemia (AML), it's a sudden and serious event that requires immediate hospitalization for chemotherapy. This time can be very challenging, with difficult physical symptoms and immense emotional distress due to the shock of diagnosis, uncertainty, and isolation. Since there aren't many ways to support patients during this tough period, researchers created a new digital app called DREAMLAND. This app offers supportive guidance and education to help patients cope with their diagnosis and manage their well-being while undergoing treatment.
Why it matters
Potential benefit: If successful, this app could provide much-needed emotional support and improve the quality of life for patients undergoing intensive chemotherapy for acute myeloid leukemia.
How similar studies have gone: This project involves a newly developed digital application, suggesting a novel approach to providing supportive care for AML patients.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: El-Jawahri, Areej — Massachusetts General Hospital
- Study coordinator: El-Jawahri, Areej
Related research
Other NIH-funded projects on the same topics.
-
Digital app to support AML patients during hospitalization
A digital app called DREAMLAND is being tested to help people with acute myeloid leukemia feel better physically and emotionally during the first 4–6 weeks of hospitalization and chemotherapy.
-
A digital app to help patients with acute myeloid leukemia cope with their diagnosis and treatment.
This study is testing a new app called DREAMLAND that helps people with acute myeloid leukemia feel better emotionally and cope with the challenges of chemotherapy, making their hospital experience more supportive and positive.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.